PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
LABP vs. SLNO
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


LABPSLNO

Fundamentals


LABPSLNO
Market Cap$71.68M$2.55B
EPS-$4.00-$2.79
Total Revenue (TTM)$0.00$3.45M
EBITDA (TTM)-$15.61M-$133.09M

Correlation

-0.50.00.51.00.2

The correlation between LABP and SLNO is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

LABP vs. SLNO - Performance Comparison

The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


-10.00%0.00%10.00%20.00%30.00%40.00%JuneJulyAugustSeptemberOctoberNovember
3.30%
38.27%
LABP
SLNO

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

LABP vs. SLNO - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Landos Biopharma, Inc. (LABP) and Soleno Therapeutics, Inc. (SLNO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


LABP
Sharpe ratio
The chart of Sharpe ratio for LABP, currently valued at 2.80, compared to the broader market-4.00-2.000.002.004.002.80
Sortino ratio
The chart of Sortino ratio for LABP, currently valued at 10.31, compared to the broader market-4.00-2.000.002.004.006.0010.31
Omega ratio
The chart of Omega ratio for LABP, currently valued at 3.34, compared to the broader market0.501.001.502.003.34
Calmar ratio
The chart of Calmar ratio for LABP, currently valued at 5.09, compared to the broader market0.002.004.006.005.09
Martin ratio
The chart of Martin ratio for LABP, currently valued at 95.20, compared to the broader market0.0010.0020.0030.0095.20
SLNO
Sharpe ratio
The chart of Sharpe ratio for SLNO, currently valued at 2.78, compared to the broader market-4.00-2.000.002.004.002.78
Sortino ratio
The chart of Sortino ratio for SLNO, currently valued at 3.27, compared to the broader market-4.00-2.000.002.004.006.003.27
Omega ratio
The chart of Omega ratio for SLNO, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for SLNO, currently valued at 3.01, compared to the broader market0.002.004.006.003.01
Martin ratio
The chart of Martin ratio for SLNO, currently valued at 13.52, compared to the broader market0.0010.0020.0030.0013.52

LABP vs. SLNO - Sharpe Ratio Comparison


Rolling 12-month Sharpe Ratio1.001.502.002.503.003.504.004.50JuneJulyAugustSeptemberOctoberNovember
2.80
2.78
LABP
SLNO

Dividends

LABP vs. SLNO - Dividend Comparison

Neither LABP nor SLNO has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

LABP vs. SLNO - Drawdown Comparison


-80.00%-60.00%-40.00%-20.00%0.00%JuneJulyAugustSeptemberOctoberNovember
-85.90%
0
LABP
SLNO

Volatility

LABP vs. SLNO - Volatility Comparison

The current volatility for Landos Biopharma, Inc. (LABP) is 0.00%, while Soleno Therapeutics, Inc. (SLNO) has a volatility of 6.85%. This indicates that LABP experiences smaller price fluctuations and is considered to be less risky than SLNO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%JuneJulyAugustSeptemberOctoberNovember0
6.85%
LABP
SLNO

Financials

LABP vs. SLNO - Financials Comparison

This section allows you to compare key financial metrics between Landos Biopharma, Inc. and Soleno Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Values in USD except per share items